Application of micro peptide MIAC
By developing micropeptide MIAC encoded by non-coding RNA, the problem of heterogeneity of different tumor tissues is solved, the inhibition of growth and migration of multiple tumor cells is achieved, and a wide range of applicable tumor treatment plans are provided.
Patent Information
- Application Number
- CN202310544241.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-15
- Publication Date
- 2024-11-15
AI Technical Summary
The genetic, phenotype and immune heterogeneity of different tumor tissues makes the application of existing micropeptides in tumor treatment limited, and there is a lack of effective solutions for a variety of tumors.
Develop a micropeptide MIAC encoded by non-coding RNA with 51 amino acid sequences MERAGVPGFSPRRSSVEAKMQSTSCSVRKSSTVTAWPAVVLLLSWGQRRGG, used to prepare reagents for detection, prevention or treatment of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer and other tumors. or drugs, by inhibiting the growth, migration and proliferation of tumor cells.
It significantly inhibits the proliferation and migration of a variety of tumor cells, especially the in vivo growth of hepatocarcinoma Hep3B cells, and provides a wide range of applicable malignant tumor diagnosis and treatment options.
Smart Images

Figure CN118957059A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of biomedicine technology, and specifically relates to an application of a micropeptide MIAC. Background Art
[0002] Open reading frames (ORFs) are potentially translatable sequences that consist of a string of in-frame sense codons that begin with a start codon and end with a stop codon. Translatable ORFs are usually annotated as coding DNA sequences (CDS) on mRNA, which are responsible for protein translation.
[0003] Long noncoding RNA (lncRNA) is a type of noncoding RNA with a length greater than 200 nt. They are expressed in a tissue- and development-specific manner and have been shown to directly regulate a variety of functions. LncRNA also contains short open reading frames (sORFs), which are generally less than 300 nt in length and were previously thought to have no coding ability. However, recent studies have shown that some sORFs have coding ability, and their encoded products are defined as micropeptides.
[0004] From bacteria to humans, an increasing number of micropeptides of less than 150 amino acids have been found in various organisms. The functional diversity of these micropeptides and the emergence of new methods for identifying them have attracted the attention of the scientific community. All these studies have shown that micropeptides translated from sORFs play important regulatory roles in many important physiological processes, such as muscle development, amino acid metabolism, immune regulation, tumor growth and cell death.
[0005] Maolei Zhang et al. discovered a lncRNA with potential coding ability by analyzing circular RNA sequencing (circRNAseq) and ribosomal nascent peptide complex sequencing (RNC-seq) of glioma cells. The experiment found that its second exon can form a circular RNA (circRNA) and translate into a micropeptide of 87 amino acids. In vivo and in vitro experiments showed that the micropeptide can inhibit the proliferation of gliomas and interact with the polymerase complex-related factor PAF1 to inhibit the transcriptional elongation of multiple proto-oncogenes. Clinical sample analysis showed that compared with adjacent tissues, the micropeptide was significantly lower in breast cancer, liver cancer, and gastric cancer, suggesting its potential role in the diagnosis and treatment of malignant tumors (Zhang M, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018 Oct 26; 9(1): 4475.).
[0006] In the related technology, for example, the Chinese invention patent with publication number CN112442116A records the application of micropeptides encoded by lncRNA in the detection and treatment of malignant tumors such as head and neck cancer, thyroid cancer, and kidney cancer.
[0007] However, different tumor tissues have genetic, phenotypic and immune heterogeneity, and little is known about the research on micropeptides, including tumor treatment. It is necessary to explore their application in the treatment of different tumors. In order to further expand the spectrum of other tumors where MIAC may play a role, the present invention attempts to detect the expression of MIAC in different tumor cells and corresponding normal cells, and uses in vivo and in vitro experimental systems to evaluate the activity of micropeptide MIAC in different tumors, thereby providing a new solution for tumor treatment. Summary of the invention
[0008] 1. Purpose of the Invention
[0009] The purpose of the present invention is to provide an application of a micropeptide MIAC. After long-term exploration and continuous attempts, the inventors have found that the micropeptide MIAC having the amino acid sequence shown in SEQ ID NO: 1 can be used to prepare reagents or drugs for detecting, preventing or treating tumors such as pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, prostate cancer, etc.
[0010] 2. Technical solution
[0011] In order to solve the above problems, the technical solutions adopted in this application are as follows:
[0012] The present application provides a use of a micropeptide MIAC in the preparation of an agent or drug for detecting, preventing or treating a tumor. The micropeptide has an amino acid sequence as shown in SEQ ID NO: 1. The amino acid sequence of SEQ ID NO: 1 is: MERAGVPGFSPRRSSVEAKMQSTSCSVRKSSTVTAWPAVVLLLSWGQRRGG.
[0013] Furthermore, the above-mentioned tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
[0014] Furthermore, the above-mentioned agent or drug for preventing or treating tumors contains at least the micropeptide MIAC with the amino acid sequence shown in SEQ ID NO: 1 and a pharmaceutically acceptable carrier.
[0015] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting the growth, migration and / or proliferation of tumor cells.
[0016] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting the proliferation of tumor cells.
[0017] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting tumor cell migration.
[0018] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting the growth of tumor cells, especially the growth of tumor cells in the body.
[0019] Furthermore, the tumor cells inhibiting the proliferation of tumor cells include:
[0020] The pancreatic cancer cells include: any one or a combination of MIP-PaCa-2, Aspc-1 and PANC-1;
[0021] The liver cancer cells include: any one or a combination of HepG2, SMMC-7721, HCCLM3, QGY-7701 and Hep3B;
[0022] The colorectal cancer cells include: any one or a combination of LOVO, SW480 and HCT-116;
[0023] The ovarian cancer cancer cells include: SKOV3 and / or A2780;
[0024] The cancer cells of cervical cancer include: Hela and / or SIHA;
[0025] The bladder cancer cancer cells include: T24 and / or EJ;
[0026] The melanoma cancer cells include: any one or a combination of A375, SK-mel-2 and M14;
[0027] The glioblastoma cancer cells include: U87-MG;
[0028] The neuroblastoma cancer cells include: SH-SY5Y;
[0029] The glioma cancer cells include: SHG-44;
[0030] The osteosarcoma cancer cells include: any one or a combination of MG-63, Saos-2 and U-2OS;
[0031] The lymphoma cancer cells include: any one or a combination of U937, Raji, U2932, WSU-DLCL2, OCI-LY10 and JeKo-1;
[0032] The cancer cells of the blood tumor include: any one or a combination of NB4, Reh, K562, Thp-1, JurKat and HL60;
[0033] The myeloma cancer cells include: any one or a combination of NCI-H929, ARP-1 and RPMI-8226;
[0034] The cholangiocarcinoma cancer cells include: QBC939;
[0035] and / or,
[0036] The prostate cancer cells include: Du145 cells.
[0037] Furthermore, the tumor cells inhibiting tumor cell migration include: prostate cancer Du145 cells, cervical cancer Hela cells, osteosarcoma MG-63 cells, ovarian cancer SKOV3 cells, melanoma A375 cells and / or liver cancer Hep3B cells.
[0038] Furthermore, the tumor cells inhibiting the growth of tumor cells include: liver cancer Hep3B cells.
[0039] The present application also provides the use of nucleotides encoding the amino acid sequence shown in SEQ ID NO: 1 in the preparation of reagents or drugs for detecting, preventing or treating tumors.
[0040] Furthermore, the above-mentioned tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
[0041] Further, the above-mentioned nucleotides contain the nucleotide sequence shown in SEQ ID NO: 2, and the nucleotide sequence shown in SEQ ID NO: 2 is: atggagagagcaggggtgcccgggttctctccgcggcgctcatcggtggaggcgaagatgcagagcaccagctgcagtgtcaggaagagctccacagtcaccgcctggccagccgtcgtgctgttgctgagctggggacagagaagaggcggatga.
[0042] The present application also provides a use of a recombinant vector in preparing a tumor reagent or drug for detecting, preventing or treating a tumor, wherein the recombinant vector encodes the amino acid sequence shown in SEQ ID NO: 1 or contains the nucleotide sequence shown in SEQ ID NO: 2.
[0043] Furthermore, the above-mentioned tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
[0044] A pharmaceutical composition for treating tumors, which contains at least the above-mentioned micropeptide MIAC, the above-mentioned nucleotide, or the above-mentioned recombinant vector, and a pharmaceutically acceptable carrier. The tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
[0045] The present application also provides a method for detecting, preventing or treating tumors, which comprises administering a micropeptide MIAC comprising the amino acid sequence shown in SEQ ID NO: 1, or a pharmaceutical composition comprising the micropeptide MIAC to a subject in need thereof.
[0046] Furthermore, the above-mentioned subject can be a human, a mouse, or a monkey.
[0047] Furthermore, in the above method, 0.1-50 mg / kg, 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 5-20 mg / kg, 10-20 mg / kg or 5-15 mg / kg of the micropeptide MIAC is administered to the subject.
[0048] 3. Beneficial effects
[0049] Compared with the prior art, the present application has the following beneficial effects:
[0050] (1) The expression level of the micropeptide MIAC provided in the present application in human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer cells is significantly lower than that in the corresponding normal cells.
[0051] (2) The application of the micropeptide MIAC provided in the present application can significantly inhibit the proliferation of tumor cells of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, and bile duct cancer, as well as inhibit the migration of tumor cells of prostate cancer, cervical cancer, osteosarcoma, ovarian cancer, melanoma, and liver cancer.
[0052] (3) Application of the micropeptide MIAC provided in the present application, which can significantly inhibit the in vivo growth of liver cancer, especially liver cancer Hep3B cell tumors.
[0053] (4) The micropeptide MIAC provided in the present application has the effect of inhibiting the proliferation and migration of various tumor cells, as well as the growth of liver cancer tumors in vivo. It has a wide therapeutic spectrum and is suitable for the diagnosis, prevention or treatment of various tumors, especially malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 It is the result of analyzing the expression of micropeptide MIAC in different tumor cells and normal cells;
[0055] Figure 2A This is the statistical result of the micropeptide MIAC inhibiting the migration activity of prostate cancer Du145 cells;
[0056] Figure 2B This is the cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition of prostate cancer Du145 cell migration activity test;
[0057] Figure 3A This is the statistical result of the micropeptide MIAC inhibiting the migration activity of cervical cancer Hela cells;
[0058] Figure 3B This is the cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition of cervical cancer Hela cell migration activity test;
[0059] Figure 4A This is the statistical result of the micropeptide MIAC inhibiting the migration activity of osteosarcoma MG-63 cells;
[0060] Figure 4B This is the cell staining picture of the blank group and each drug-treated group in the micropeptide MIAC inhibition of osteosarcoma MG-63 cell migration activity test;
[0061] Figure 5A This is the statistical result of the micropeptide MIAC inhibiting the migration activity of ovarian cancer SKOV3 cells;
[0062] Figure 5B This is the cell staining picture of the blank group and each drug-treated group in the micropeptide MIAC inhibition of ovarian cancer SKOV3 cell migration activity test;
[0063] Fig. 6A This is the statistical result of the micropeptide MIAC's inhibitory activity on the migration of malignant melanoma A375 cells;
[0064] Figure 6B This is the cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of malignant melanoma A375 cells;
[0065] Fig. 7A This is the statistical result of the micropeptide MIAC inhibiting the migration activity of liver cancer Hep3B cells;
[0066] Figure 7B This is the cell staining picture of the blank group and each drug-treated group in the micropeptide MIAC inhibition of liver cancer Hep3B cell migration activity test;
[0067] Figure 8 The in vivo growth curve of MIAC inhibiting Hep3B subcutaneous transplanted tumors in nude mice in Example 4;
[0068] Fig. 9 This is a statistical graph of the tumor weight on the 22nd day after MIAC inhibited subcutaneous transplantation of nude mice with liver cancer Hep3B cells in Example 4. DETAILED DESCRIPTION
[0069] The present application is further described below in conjunction with specific embodiments.
[0070] It should be noted that the terms such as "upper", "lower", "left", "right", "middle", etc. cited in this specification are only for the convenience of description and are not used to limit the scope of implementation. Changes or adjustments to their relative relationships should be regarded as the scope of implementation of this application without substantially changing the technical content.
[0071] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs; the term "and / or" used herein includes any and all combinations of one or more of the associated listed items.
[0072] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.
[0073] As used herein, the term "about" is used to provide flexibility and imprecision associated with a given term, measurement or value. The degree of flexibility for a particular variable can be easily determined by one skilled in the art.
[0074] As used herein, the term "at least one of" is intended to be synonymous with "one or more of." For example, "at least one of A, B, and C" expressly includes only A, only B, only C, and combinations of each thereof.
[0075] Concentration, amount and other numerical data can be presented in range format herein.It should be understood that such range format is only used for convenience and simplicity, and should be flexibly interpreted as not only including the numerical value clearly described as range limit, but also including all single numerical values or sub-ranges contained in the range, just as each numerical value and sub-range are clearly described.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly described, but also including single numerals (such as 2,3,4) and sub-ranges (such as 1 to 3,2 to 4, etc.).The same principle is applicable to the scope of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all the above-mentioned values and ranges.In addition, no matter how the breadth of the described range or feature is, this explanation should be applicable.
[0076] Micropeptide Inhibiting Actin Cytoskeleton (MIAC) is a human endogenous protein or polypeptide fragment with 51 amino acids encoded by non-coding RNA (lncRNA). The micropeptide MIAC has an amino acid sequence: MERAGVPGFSPRRSSVEAKMQSTSCSVRKSSTVTAWPAVVLLLSWGQRRGG (SEQ ID NO: 1).
[0077] The present application provides the use of the above-mentioned micropeptide MIAC in the preparation of reagents or drugs for detecting, preventing or treating tumor diseases.
[0078] In some embodiments, the tumor comprises a solid tumor or a hematological tumor.
[0079] In some embodiments, the tumor comprises pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and / or prostate cancer.
[0080] The micropeptide MIAC provided in the present application has the effect of inhibiting the growth, migration and / or proliferation of tumor cells in vivo and / or in vitro.
[0081] In some embodiments, the micropeptide MIAC has an inhibitory effect on the proliferation of various tumor cells including the following:
[0082] Pancreatic cancer cancer cells, comprising: any one or a combination of MIP-PaCa-2, Aspc-1 and PANC-1;
[0083] Hepatocellular carcinoma cancer cells, including any one or a combination of HepG2, SMMC-7721, HCCLM3, QGY-7701 and Hep3B;
[0084] Colorectal cancer cancer cells, including: any one or a combination of LOVO, SW480 and HCT-116;
[0085] Ovarian cancer cancer cells, including: SKOV3 and / or A2780;
[0086] Cervical cancer cells, including Hela and / or SIHA;
[0087] Bladder cancer cells, including: T24 and / or EJ;
[0088] Melanoma cancer cells, including: any one or a combination of A375, SK-mel-2 and M14;
[0089] Glioblastoma cancer cells, including: U87-MG;
[0090] For neuroblastoma, cancer cells include: SH-SY5Y;
[0091] Glioma cancer cells, including: SHG-44;
[0092] Osteosarcoma cancer cells, including: any one or a combination of MG-63, Saos-2 and U-2OS;
[0093] Lymphoma cancer cells, including any one or a combination of U937, Raji, U2932, WSU-DLCL2, OCI-LY10 and JeKo-1;
[0094] Hematological cancer cells, including any one or a combination of NB4, Reh, K562, Thp-1, JurKat and HL60;
[0095] Myeloma cancer cells, including: any one or a combination of NCI-H929, ARP-1 and RPMI-8226;
[0096] Cholangiocarcinoma cancer cells, including: QBC939;
[0097] Prostate cancer cells, including Du145 cells.
[0098] The micropeptide MIAC provided in the present application has the effect of inhibiting tumor cell proliferation in the range of 50-200 μM, 10-200 μM, and 50-100 μM.
[0099] In some embodiments, the micropeptide MIAC can also inhibit the migration of tumor cells, specifically including: human prostate cancer Du145 cells, human cervical cancer Hela cells, human osteosarcoma MG-63 cells, human ovarian cancer SKOV3 cells, human malignant melanoma A375 cells and / or human liver cancer Hep3B cells.
[0100] Optionally, the micropeptide MIAC can inhibit tumor cell migration in the range of 0.78-50 μM, 0.78-25 μM, 1.56-50 μM, 3.125-50 μM, 6.25-50 μM, 25-50 μM or 12.5-50 μM.
[0101] The micropeptide MIAC provided in the present application can inhibit the in vivo growth of tumor cells. Optionally, MIAC can inhibit the in vivo tumor growth of human liver cancer cells. In some embodiments, the micropeptide MIAC inhibits the in vivo tumor growth of liver cancer Hep3B cells.
[0102] Therefore, the present application also provides a method for detecting, preventing or treating tumor diseases, which comprises administering a micropeptide MIAC comprising or having the amino acid sequence shown in SEQ ID NO: 1, or a pharmaceutical composition comprising the micropeptide MIAC to a subject in need thereof.
[0103] The subject can be selected from humans, mice, monkeys, dogs, pigs. In some embodiments, the subject is humans, monkeys, dogs or mice.
[0104] When a pharmaceutical composition comprising the micropeptide MIAC is administered to a subject, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.
[0105] The term "pharmaceutically acceptable carrier" refers to an excipient or carrier that does not cause significant irritation to the subject and does not abrogate the biological activity and properties of the administered anti-mesothelin antibody or antigen-binding fragment thereof and / or any additional therapeutic agent in the composition. A pharmaceutically acceptable carrier can enhance or stabilize the composition, or can be used to facilitate the preparation of the composition.
[0106] The pharmaceutical composition comprising the micropeptide MIAC can select a suitable administration method according to the specific applicable form, physicochemical characteristics, etc. of the pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition can be formed into a preparation in the form of a freeze-dried preparation or a liquid preparation, and the preparation may contain a suitable preparation additive in the art. For example, in the above-mentioned pharmaceutical composition, representatively, more than one pharmaceutical excipient is contained, such as a sterilized liquid, such as water and oil (including oils of petroleum, animal, plant, or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.)). In the case of intravenous administration of the above-mentioned pharmaceutical composition, water is a more representative carrier. In addition, saline solution, as well as glucose aqueous solution and glycerol aqueous solution can also be used as liquid carriers, especially for injection solutions. Suitable pharmaceutical excipients are known in the art. As needed, the composition may also contain a trace amount of a wetting agent or an emulsifier, or a pH buffering agent. The pharmaceutical composition is usually administered parenterally, and may be injected intradermally, intramuscularly, intraperitoneally, intravenously or subcutaneously, but is not limited thereto. For example, it may be administered by infusion or bolus injection, intracranial, intrathecal or intranasal (e.g., inhalation), intradermally, subcutaneously or transmucosally.
[0107] When using micropeptide MIAC to detect, prevent or treat tumors, the dosage is varied according to the specific condition being treated, the severity of the condition, individual patient parameters (including age, physical condition, size, sex and weight), duration of treatment, the nature of concurrent therapy (if any), the specific route of administration, and the knowledge of the physician or veterinarian, and the dosage is gradually increased until the desired effect is achieved. In some embodiments, the dosage of the active ingredient can be determined empirically in individuals who have been given one or more micropeptide MIAC administrations.
[0108] In some embodiments, for example, when 0.1-50 mg / kg, 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 5-20 mg / kg, 10-20 mg / kg or 5-15 mg / kg of the micropeptide MIAC is administered to a subject, the tumorigenicity of tumor cells can be significantly inhibited, in particular, the tumorigenicity of tumor cells in vivo can be inhibited.
[0109] In some embodiments, the dose administered to the subject can be converted between species, such as between humans and mice. The conversion method is known in the art, see, for example, "Pharmacological Experimental Methodology" Xu Shuyun. Pharmacological Experimental Methodology. 2nd Edition [M]. People's Medical Publishing House, 1991, the contents of each of which are hereby incorporated by reference herein.
[0110] The technical solution of the present invention will be more clearly and explicitly described in the following examples in an illustrative manner. It should be understood that these examples are only for illustrative purposes and are by no means intended to limit the scope of protection of the present invention. The scope of protection of the present invention is only limited by the claims.
[0111] Example 1
[0112] This example detects the expression of the micropeptide MIAC in different tumor cells and normal cells.
[0113] (1) Cell culture and RNA extraction
[0114] Human pancreatic ductal epithelial cells HPDE, pancreatic cancer cells PANC-1, Aspc-1; human normal liver cells L02, liver cancer cells HepG2, QGY-7701, Hep3B; human normal colon cells CCD-18Co, colorectal cancer cells SW480, HCT-116; human normal ovarian epithelial cells IOSE-80, ovarian cancer cells SKOV3, A2780; human cervical epithelial cells HCerEpiC, cervical cancer cells Hela, SIHA; human normal bladder epithelial cells SV-HUC-1, bladder cancer cells T24, EJ; human epidermal keratinocytes HEKa, melanocytes SK-mel-2, M14; human brain glial cells T98G, glial Tumor cells SHG-44, neuroblastoma cells SH-SY5Y; human osteoblast cell line hFOB1.19, osteosarcoma cells MG-63, U-2OS; human T lymphocytes H9, lymphoma cells U2932, WSU-DLCL2, JeKo-1; human peripheral blood mononuclear cells PBMC, hematological tumor cells K562, HL60, NCI-H929, RPMI-8226; human intrahepatic bile duct epithelial cells HIBEpiC, cholangiocarcinoma cells QBC939; human prostate epithelial cells HPEpiC and prostate cancer cells Du145 were cultured in an incubator at 37°C and 5% CO2 to a density of 90%, the supernatant was discarded, a certain volume of Trizol (Life Invitrogen) was added, and total RNA from different cells was extracted according to the instructions.
[0115] (2) Primer design
[0116] Primers were designed based on the nucleotide sequence information encoding the micropeptide MIAC, and the sequences are as follows:
[0117] Upstream primer (SEQ ID NO. 3): ATGGAGAGAGCAGGGGTGCCCG;
[0118] Downstream primer (SEQ ID NO. 4): CGCCTCTTCTCTGTCCCCAGCTC.
[0119] (3) Real-time quantitative PCR was used to detect the expression of micropeptide MIAC in different tumor cells and normal cells.
[0120] The total RNA extracted in the above steps was quantified by NanoDrop ND-1000 nucleic acid quantifier for purity and concentration, and agarose quality inspection ensured the integrity of the extracted RNA. The TaKaRa kit PrimeScriptTMRT reagent Kit with gDNA Eraser (Perfect Real Time) was used to reverse transcribe the extracted total RNA into cDNA. Premix Ex Taq TM II (Tli RNaseH Plus) for qPCR reaction. The reaction system is shown in Table 1. After the above components are mixed evenly, the following procedures are followed: 95°C 30s pre-denaturation, 40 cycles; 95°C 5s, 60°C 30s.
[0121] Table 1 PCR reaction system
[0122]
[0123] The specificity of the reaction was determined based on the melting curve, and the relative expression of MIAC was calculated using the formula 2-ΔΔCt. Figure 1 Compared with the corresponding normal cells, the expression levels of MIAC in human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, myeloma, lymphoma, hematological tumor and bile duct cancer cells were significantly lower than those in normal cells. Therefore, the anti-tumor effect of MIAC was subsequently investigated in the above-mentioned tumor cells.
[0124] Example 2
[0125] This example provides the inhibitory effect of the micropeptide MIAC on the proliferation of human tumor cells.
[0126] Human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, myeloma, lymphoma, hematological tumor and bile duct cancer cells were cultured in an incubator at 37°C and 5% CO2 until the density reached 90%, then digested and collected with trypsin, resuspended in culture medium and counted under a microscope to adjust the cell concentration to about 1.0×10 5 / mL, the cell suspension was inoculated into a 96-well plate, 100μL per well, and cultured overnight in a 37°C, 5% CO2 incubator. After the cells were completely attached, 100μL of micropeptide MIAC with concentrations of 50μM, 100μM, and 200μM were added as the drug-treated group; the culture medium without any drug was used as the negative control group. After incubation for 72h, 100μL CCK8 was added to each well of the 96-well plate to dissolve. The absorbance OD was measured at a detection wavelength of 450nm using an enzyme reader, and the growth inhibition rate (PI) was calculated, the formula was: PI (%) = 1-drug-treated group / negative control group. The experiment was repeated 3 times independently, the results were expressed as Mean±SD, and a statistical T test was performed, *P<0.05 was a significant difference, **P<0.01 was an extremely significant difference. The results are shown in Tables 2-52.
[0127] Table 2 The inhibitory effect of micropeptide MIAC on the proliferation of human pancreatic cancer cell PANC-1
[0128]
[0129] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0130] Table 3 The inhibitory effect of micropeptide MIAC on the proliferation of human pancreatic cancer cell Aspc-1
[0131]
[0132] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0133] Table 4 The inhibitory effect of micropeptide MIAC on the proliferation of human pancreatic cancer cell MIP-PaCa-2
[0134]
[0135] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0136] Table 5 The inhibitory effect of micropeptide MIAC on the proliferation of human esophageal cancer cell Eca-109
[0137]
[0138] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0139] Table 6 The inhibitory effect of micropeptide MIAC on the proliferation of human esophageal cancer cell CaES-17
[0140]
[0141] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0142] Table 7 Inhibitory effect of micropeptide MIAC on proliferation of human gastric cancer cell BGC-803
[0143]
[0144]
[0145] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0146] Table 8 Inhibitory effect of micropeptide MIAC on proliferation of human gastric cancer cell BGC-823
[0147]
[0148] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0149] Table 9 Inhibitory effect of micropeptide MIAC on proliferation of human liver cancer cell HepG2
[0150]
[0151] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0152] Table 10 Micropeptide MIAC inhibits proliferation of human hepatoma cell line SMMC-7721
[0153]
[0154] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0155] Table 11 The inhibitory effect of micropeptide MIAC on the proliferation of human hepatoma cell line HCCLM3
[0156]
[0157] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0158] Table 12 Micropeptide MIAC inhibits proliferation of human liver cancer cell QGY-7701
[0159]
[0160] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0161] Table 13 The inhibitory effect of micropeptide MIAC on the proliferation of human colon cancer cells LOVO
[0162]
[0163] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0164] Table 14 The inhibitory effect of micropeptide MIAC on the proliferation of human colon cancer cell SW480
[0165]
[0166] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0167] Table 15 The inhibitory effect of micropeptide MIAC on the proliferation of human colon cancer cell HCT-116
[0168]
[0169] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0170] Table 16 The inhibitory effect of micropeptide MIAC on the proliferation of human breast cancer cells MX-1
[0171]
[0172] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0173] Table 17 Micropeptide MIAC inhibits proliferation of human breast cancer cells MDA-MB-231
[0174]
[0175] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0176] Table 18 Micropeptide MIAC inhibits proliferation of human breast cancer cells MCF-7
[0177]
[0178]
[0179] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0180] Table 19 The inhibitory effect of micropeptide MIAC on the proliferation of human ovarian cancer cell SKOV3
[0181]
[0182] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0183] Table 20 Micropeptide MIAC inhibits proliferation of human ovarian cancer cell A2780
[0184]
[0185] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0186] Table 21 Micropeptide MIAC inhibits proliferation of human cervical cancer cells Hela
[0187]
[0188] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0189] Table 22 Micropeptide MIAC inhibits proliferation of human cervical cancer cells SIHA
[0190]
[0191] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0192] Table 23 Micropeptide MIAC inhibits proliferation of human non-small cell lung cancer cells NCI-H1299
[0193]
[0194] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0195] Table 24 Micropeptide MIAC inhibits proliferation of human non-small cell lung cancer cells NCI-H1650
[0196]
[0197]
[0198] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0199] Table 25 Micropeptide MIAC inhibits proliferation of human lung giant cell carcinoma cell line 95-D
[0200]
[0201] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0202] Table 26 Micropeptide MIAC inhibits proliferation of human bladder transitional cell carcinoma cell T24
[0203]
[0204] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0205] Table 27 Micropeptide MIAC inhibits proliferation of human bladder cancer cells EJ
[0206]
[0207] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0208] Table 28 Micropeptide MIAC inhibits proliferation of human malignant melanoma cells A375
[0209]
[0210] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0211] Table 29 Micropeptide MIAC inhibits proliferation of human malignant melanoma cells SK-mel-2
[0212]
[0213] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0214] Table 30 Micropeptide MIAC inhibits proliferation of human malignant melanoma cells M14
[0215]
[0216] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0217] Table 31 Micropeptide MIAC inhibits proliferation of human brain glioblastoma cells U87-MG
[0218]
[0219] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0220] Table 32 Micropeptide MIAC inhibits proliferation of human neuroblastoma cells SH-SY5Y
[0221]
[0222] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0223] Table 33 Micropeptide MIAC inhibits proliferation of human glioma cells SHG-44
[0224]
[0225] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0226] Table 34 Micropeptide MIAC inhibits proliferation of human osteosarcoma cells MG-63
[0227]
[0228] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0229] Table 35 Micropeptide MIAC inhibits proliferation of human osteosarcoma cells Saos-2
[0230]
[0231]
[0232] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0233] Table 36 Micropeptide MIAC inhibits proliferation of human osteosarcoma cells U-2OS
[0234]
[0235] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0236] Table 37 Micropeptide MIAC inhibits proliferation of human histiocytic lymphoma cells U937
[0237]
[0238] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0239] Table 38 Micropeptide MIAC inhibits proliferation of human lymphoma cells Raji
[0240]
[0241] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0242] Table 39 Micropeptide MIAC inhibits proliferation of human diffuse large B-cell lymphoma U2932 cells
[0243]
[0244] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0245] Table 40 Micropeptide MIAC inhibits proliferation of human diffuse large B-cell lymphoma WSU-DLCL2
[0246]
[0247] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0248] Table 41 Micropeptide MIAC inhibits proliferation of human diffuse large B-lymphoma cells OCI-LY10
[0249]
[0250]
[0251] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0252] Table 42 Micropeptide MIAC inhibits proliferation of human mantle cell lymphoma cells JeKo-1
[0253]
[0254] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0255] Table 43 Micropeptide MIAC inhibits proliferation of human acute promyelocytic leukemia cells NB4
[0256]
[0257] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0258] Table 44 Micropeptide MIAC inhibits proliferation of human acute non-T non-B lymphocytic leukemia cells Reh
[0259]
[0260] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0261] Table 45 Micropeptide MIAC inhibits proliferation of human chronic myeloid leukemia cells K562
[0262]
[0263] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0264] Table 46 Micropeptide MIAC inhibits proliferation of human monocytic leukemia cells Thp-1
[0265]
[0266] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0267] Table 47 Micropeptide MIAC inhibits proliferation of human T lymphoma leukemia cells JurKat
[0268]
[0269] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0270] Table 48 Micropeptide MIAC inhibits proliferation of human myeloid leukemia cells HL60
[0271]
[0272] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0273] Table 49 Micropeptide MIAC inhibits proliferation of human myeloma cells NCI-H929
[0274]
[0275] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0276] Table 50 Micropeptide MIAC inhibits proliferation of human myeloma cells ARP-1
[0277]
[0278] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0279] Table 51 Micropeptide MIAC inhibits proliferation of human multiple myeloma peripheral blood B lymphocytes RPMI-8226
[0280]
[0281] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0282] Table 52 Micropeptide MIAC inhibits proliferation of human cholangiocarcinoma cell QBC939
[0283]
[0284]
[0285] Note: Compared with the negative control group, *P<0.05, **P<0.01.
[0286] It can be seen from Table 2-52 that compared with the negative control, at a dose of 50 to 200 μM, the micropeptide MIAC can significantly inhibit the proliferation of human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioma, neuroblastoma, osteosarcoma, myeloma, lymphoma, leukemia, and bile duct cancer cells to varying degrees, and shows a dose-dependent relationship.
[0287] Example 3
[0288] This example provides the inhibitory effect of the micropeptide MIAC on the migration of human tumor cells.
[0289] Human prostate cancer, cervical cancer, osteosarcoma, ovarian cancer, melanoma, and liver cancer cells were inoculated into transwell chambers, 100 μL per well, and 100 μL of different doses of micropeptide MIAC were added to each chamber as the drug-dosing group, and no drug was added to the blank group. Then 0.6 mL of complete culture medium containing 10% FBS was added to the lower chamber of the transwell to stimulate cell migration, and cultured at 5% CO2 and 37°C for 48 hours. The culture medium in the wells was discarded, fixed with methanol at room temperature for 30 minutes, stained with 0.1% crystal violet at room temperature for 10 minutes, rinsed with clean water, and the unmigrated cells on the upper layer were wiped off with a cotton swab, observed under a microscope, and four fields of view were selected for photography and counting. The migration inhibition rate (MI) was calculated according to the formula:
[0290]
[0291] Among them, N test is the number of cell migration in the drug-treated group, N control is the number of migrated cells in the blank control group.
[0292] The results are shown in Tables 53-58 and Figures 2-7.
[0293] Table 53 Inhibitory effect of MIAC on the migration activity of prostate cancer Du145 cells
[0294]
[0295] Figure 2A Corresponding to the statistical graphs of each group in Table 53; Figure 2B Corresponding to the staining images of each group of cells in the above Table 53.
[0296] Table 54 Inhibitory effect of MIAC on migration activity of cervical cancer Hela cells
[0297]
[0298]
[0299] Figure 3A Corresponding to the statistical graphs of each group in Table 54; Figure 3B Corresponding to the staining images of each group of cells in the above Table 54.
[0300] Table 55 Inhibitory effect of MIAC on the migration activity of osteosarcoma MG-63 cells
[0301]
[0302] Figure 4A Corresponding to the statistical charts of each group in Table 55; Figure 4B Corresponding to the staining images of each group of cells in the above Table 55.
[0303] Table 56 Inhibitory effect of MIAC on migration activity of ovarian cancer SKOV3 cells
[0304]
[0305] Figure 5A Corresponding to the statistical graphs of each group in Table 56; Figure 5B Corresponding to the staining images of each group of cells in the above Table 56.
[0306] Table 57 Inhibitory effect of MIAC on the migration activity of malignant melanoma A375 cells
[0307]
[0308] Fig. 6A Corresponding to the statistical graphs of each group in Table 57; Figure 6B Corresponding to the staining images of each group of cells in the above Table 57.
[0309] Table 58 Inhibitory effect of MIAC on the migration activity of liver cancer Hep3B cells
[0310]
[0311] Fig. 7A Corresponding to the statistical charts of each group in Table 58; Figure 7B Corresponding to the staining images of each group of cells in the above Table 58.
[0312] It can be seen from Tables 53-58 and Figures 2-7 that compared with the blank control, the micropeptide MIAC has a significant inhibitory effect on the migration of human prostate cancer Du145 cells, human osteosarcoma MG-63 cells, human ovarian cancer SKOV3 cells, human liver cancer Hep3B cells, human melanoma A375 cells, and human cervical cancer Hela cells within a certain range, and the inhibition rate is dose-dependent, indicating that the micropeptide MIAC can be developed into an anti-tumor drug by inhibiting the migration of the above-mentioned malignant tumor cells.
[0313] Example 4
[0314] This example provides the inhibitory effect of the micropeptide MIAC on the growth of human tumor cells in vivo.
[0315] Human hepatoma cell line Hep3B was cultured in large quantities and digested with 0.25% trypsin solution. After digestion, the cell suspension was centrifuged at 1000 rpm for 5 min. The cells were resuspended in serum-free MEM medium and counted. The cell concentration was adjusted to 5 × 10 7 Each BALB / c nude mouse (4-6 weeks old, female, weighing 14-16 g, adapted for 1 week in an SPF animal breeding room) was inoculated with 100 μL of cell suspension in the left axilla, with an injection volume of 5×10 6 After inoculation, the tumor growth at the inoculation site of nude mice was closely observed. On the 7th day after inoculation, white nodules appeared at the inoculation site, which could be moved subcutaneously after being touched. As the tumor tissue grew, a hard tumor mass gradually formed at the inoculation site. The average volume of the tumor tissue reached 100 mm in about 14 days. 3 BALB / c nude mice were randomly divided into 7 groups (normal saline group as blank control, 5mg / kg of MIAC as low dose, 10mg / kg of MIAC as medium dose, 15mg / kg of MIAC as medium-high dose, 20mg / kg of MIAC as high dose, 15mg / kg of oxaliplatin and 50mg / kg of sorafenib as positive control), 10 in the blank group, 6 in each of the other groups, and the weight of the animals was about 20g at the beginning of drug administration. The transplanted tumor volume was measured and recorded every two days, and the tumor volume (Tumor volume, TV) was calculated as follows: Tumor volume = 0.5×a×b 2 , where a is the length of the transplanted tumor (mm) and b is the width of the transplanted tumor (mm).
[0316] Results Figure 8 and Fig. 9 Compared with the blank control group, the micropeptide MIAC can significantly inhibit the in vivo tumor growth of human liver cancer cell Hep3B to varying degrees, and it shows a dose-dependent relationship. At a dose of 20 mg / kg, the therapeutic effect on tumors is similar to that of positive drugs, indicating that the micropeptide MIAC has a good in vivo anti-tumor effect.
Claims
1. Use of a micropeptide MIAC in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The micropeptide MIAC has an amino acid sequence as shown in SEQ ID NO: 1; the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
2. The use of a micropeptide MIAC according to claim 1 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The agent or drug for preventing or treating tumors contains at least micropeptide MIAC and a pharmaceutically acceptable carrier.
3. Use of a micropeptide MIAC according to claim 1 or 2 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The prevention or treatment of tumors includes inhibiting the growth, migration and / or proliferation of tumor cells.
4. The use of a micropeptide MIAC according to claim 3 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The prevention or treatment of tumors includes: inhibiting the proliferation of tumor cells, The pancreatic cancer cells include: any one or a combination of MIP-PaCa-2, Aspc-1 and PANC-1; The liver cancer cells include: any one or a combination of HepG2, SMMC-7721, HCCLM3, QGY-7701 and Hep3B; The colorectal cancer cells include: any one or a combination of LOVO, SW480 and HCT-116; The ovarian cancer cancer cells include: SKOV3 and / or A2780; The cancer cells of cervical cancer include: Hela and / or SIHA; The bladder cancer cancer cells include: T24 and / or EJ; The melanoma cancer cells include: any one or a combination of A375, SK-mel-2 and M14; The glioblastoma cancer cells include: U87-MG; The neuroblastoma cancer cells include: SH-SY5Y; The glioma cancer cells include: SHG-44; The osteosarcoma cancer cells include: any one or a combination of MG-63, Saos-2 and U-2OS; The lymphoma cancer cells include: any one or a combination of U937, Raji, U2932, WSU-DLCL2, OCI-LY10 and JeKo-1; The cancer cells of the blood tumor include: any one or a combination of NB4, Reh, K562, Thp-1, JurKat and HL60; The myeloma cancer cells include: any one or a combination of NCI-H929, ARP-1 and RPMI-8226; The cholangiocarcinoma cancer cells include: QBC939; and / or, The prostate cancer cells include: Du145 cells.
5. Use of a micropeptide MIAC according to claim 3 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The tumor prevention or treatment comprises: inhibiting the migration of prostate cancer Du145 cells, cervical cancer Hela cells, osteosarcoma MG-63 cells, ovarian cancer SKOV3 cells, melanoma A375 cells and / or liver cancer Hep3B cells.
6. Use of a micropeptide MIAC according to claim 3 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The tumor prevention or treatment includes: inhibiting the growth of liver cancer Hep3B cells.
7. Use of a nucleotide in the preparation of a reagent or drug for detecting, preventing or treating a tumor, characterized in that: The nucleotide encodes the amino acid sequence shown in SEQ ID NO: 1; the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
8. Use of a nucleotide according to claim 7 in the preparation of a reagent or drug for detecting, preventing or treating tumors, characterized in that: The nucleotide sequence comprises the nucleotide sequence shown in SEQ ID NO:
2.
9. Use of a recombinant vector in the preparation of an agent or drug for detecting, preventing or treating a tumor, characterized in that: The recombinant vector encodes the amino acid sequence shown in SEQ ID NO: 1 or contains the nucleotide sequence shown in SEQ ID NO: 2; the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
10. A pharmaceutical composition for treating tumors, characterized in that: The pharmaceutical composition contains at least the micropeptide MIAC according to claim 1, the nucleotide according to claim 7 or 8, or the recombinant vector according to claim 9, and a pharmaceutically acceptable carrier, and the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.
Citation Information
Cited By
Novel polypeptide, polypeptide derivative and use thereof
WO2025031513A1
